1055331-73-1

Usage

Uses

Used in Pharmaceutical Synthesis:
Benzoic acid, 2-bromo-5-fluoro-3-nitro-, is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique functional groups allow for the development of new drugs with specific therapeutic properties.
Used in Agrochemical Production:
Benzoic acid, 2-broMo-5-fluoro-3-nitrois utilized in the production of agrochemicals, contributing to the development of effective pesticides and other agricultural products to protect crops and enhance yield.
Used in Dye and Perfume Manufacturing:
Benzoic acid, 2-bromo-5-fluoro-3-nitro-, is employed in the manufacturing of dyes and perfumes, where its chemical structure contributes to the creation of vibrant colors and distinct fragrances.
Used as a Reagent in Organic Chemistry:
In the realm of organic chemistry, Benzoic acid, 2-broMo-5-fluoro-3-nitro- serves as a valuable reagent, facilitating various chemical reactions and contributing to the advancement of chemical research and development.
Used in Antibacterial and Antifungal Applications:
Benzoic acid, 2-bromo-5-fluoro-3-nitro-, has been studied for its potential antibacterial and antifungal properties, making it a candidate for use in the development of new antimicrobial agents to combat resistant strains of bacteria and fungi.

Upstream product

• 394-28-5 2-Bromo-5-fluorobenzoic acid 
• 328547-12-2 methyl 2-bromo-5-fluoro-3-nitrobenzoate 

Downstream Products

• 328547-12-2 methyl 2-bromo-5-fluoro-3-nitrobenzoate 

Relevant academic research and scientific papers

ISOQUINOLINONE DERIVATIVES AS PARP INHIBITORS

Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R1-R6, R1a, R2a, R1b, R2b, R1c, R2c, p and q are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PARP enzyme of a subject.

FUSED TETRA OR PENTA-CYCLIC PYRIDOPHTHALAZINONES AS PARP INHIBITORS

Provided are certain fused tetra or penta-cyclic compounds and salts thereof, compositions thereof, and methods of use thereof.

ISOQUINOLINONE DERIVATIVES AS PARP INHIBITORS

Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R1-R6, p and q are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PARP enzyme of a subject.

FUSED TETRA OR PENTA-CYCLIC PYRIDOPHTHALAZINONES AS PARP INHIBITORS

Provided are certain fused tetra or penta-cyclic compounds and salts thereof, compositions thereof, and methods of use thereof.

FUSED TETRA OR PENTA-CYCLIC PYRIDOPHTHALAZINONES AS PARP INHIBITORS

Provided are certain fused tetra or penta-cyclic compounds and salts thereof, compositions thereof, and methods of use thereof.

TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS

This invention is directed to, for example, compounds of formula (I): wherein n, m, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment of iron disorders. This invention is also directed to pharmaceutical compositions comprising the compounds and methods of using the compounds to treat iron disorders.